Department of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Atherosclerosis. 2011 Jul;217(1):253-9. doi: 10.1016/j.atherosclerosis.2011.03.021. Epub 2011 Apr 9.
Phospholipid transfer protein (PLTP) is an emerging cardio-metabolic risk factor which is intricately involved in lipoprotein metabolism. Elevated plasma PLTP activity levels are reported in obesity and diabetes mellitus, but the relative contributions of obesity and insulin resistance to plasma PLTP activity remain unclear. We tested whether plasma PLTP activity is independently related to (central) obesity and insulin resistance in non-diabetic subjects.
The relationships of plasma PLTP activity levels (phospholipid vesicles-HDL system) with waist circumference, waist/hip ratio, body mass index (BMI) and insulin resistance (homeostasis model assessment (HOMA(ir))) were determined in 313 non-diabetic subjects (273 men).
PLTP activity was higher in 67 subjects with enlarged waist circumference (NCEP-ATP-III criteria; 102 ± 11 AU) compared to 246 subjects with normal waist (98 ± 11 AU, P=0.027). In univariate analysis PLTP activity correlated positively with waist (r=0.188), waist/hip ratio (r=0.143), BMI (r=0.125) and HOMA(ir) (r=0.192) (P<0.05 to P<0.001). The relationship of PLTP with HOMA(ir) was confined to subjects with the highest waist circumference and waist/hip ratio. In age- and sex-adjusted multiple linear regression models, waist circumference (β=0.158, P=0.025), but not BMI, predicted PLTP activity independently of HOMA(ir) (β=0.126, P=0.047). Furthermore, both waist and waist/hip ratio interacted positively with HOMA(ir) on PLTP activity (β=0.109, P=0.056 and β=0.156, P=0.034, respectively).
In non-diabetic subjects, both obesity and insulin resistance influence plasma PLTP activity, resulting in elevated plasma PLTP activity particularly with combined increases in obesity and insulin resistance. Higher PLTP activity could contribute to elevated cardiovascular risk in the presence of obesity and insulin resistance.
磷脂转运蛋白(PLTP)是一种新兴的心代谢风险因子,它与脂蛋白代谢有着复杂的关系。已有研究表明,肥胖症和糖尿病患者的血浆 PLTP 活性水平升高,但肥胖症和胰岛素抵抗对血浆 PLTP 活性的相对贡献仍不清楚。我们在非糖尿病患者中检测了血浆 PLTP 活性是否与(中心)肥胖和胰岛素抵抗独立相关。
在 313 名非糖尿病患者(273 名男性)中,确定了血浆 PLTP 活性水平(磷脂囊泡-HDL 系统)与腰围、腰围/臀围比、体重指数(BMI)和胰岛素抵抗(稳态模型评估(HOMA(ir))之间的关系。
根据 NCEP-ATP-III 标准,67 名腰围增大的患者(102±11AU)的 PLTP 活性高于 246 名腰围正常的患者(98±11AU,P=0.027)。在单变量分析中,PLTP 活性与腰围(r=0.188)、腰围/臀围比(r=0.143)、BMI(r=0.125)和 HOMA(ir)(r=0.192)呈正相关(P<0.05 至 P<0.001)。PLTP 与 HOMA(ir)的关系仅限于腰围和腰围/臀围比最高的患者。在年龄和性别调整的多元线性回归模型中,腰围(β=0.158,P=0.025),而不是 BMI,可独立于 HOMA(ir)预测 PLTP 活性(β=0.126,P=0.047)。此外,腰围和腰围/臀围比均与 HOMA(ir)呈正相关(β=0.109,P=0.056 和 β=0.156,P=0.034)。
在非糖尿病患者中,肥胖症和胰岛素抵抗均影响血浆 PLTP 活性,导致血浆 PLTP 活性升高,尤其是在肥胖症和胰岛素抵抗同时增加时。较高的 PLTP 活性可能会增加肥胖症和胰岛素抵抗患者的心血管风险。